Home Cart Sign in  
Chemical Structure| 1421373-98-9 Chemical Structure| 1421373-98-9

Structure of AZ-5104
CAS No.: 1421373-98-9

Chemical Structure| 1421373-98-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AZ5104 is an irreversible inhibitor of EGFR-L858R/T790M, EGFR-L858R, EGFR-L861Q, and EGFR (IC50s of < 1 nM, 6 nM, 1 nM, and 25 nM respectively). AZ5104 is the demethylated metabolite of AZD-9291.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AZ-5104

CAS No. :1421373-98-9
Formula : C27H31N7O2
M.W : 485.58
SMILES Code : C=CC(NC1=CC(NC2=NC=CC(C3=CNC4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O
MDL No. :MFCD28899992
InChI Key :IQNVEOMHJHBNHC-UHFFFAOYSA-N
Pubchem ID :71496460

Safety of AZ-5104

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317
Precautionary Statements:P280

Related Pathways of AZ-5104

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    EGFR (L861Q) , IC50:<1 nM

    EGFR (L858R), IC50:6 nM

  • ErbB4

    ErbB4, IC50:7 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
NR6 cells 100 nM 4 h Test the inhibitory effect of AZ5104 on HER2L869R/T798I signaling PMC5457707
PC-9 2 nmol/L 72 hours Evaluate the inhibitory activity of AZ-5104 against Del19 mutant cells PMC7745057
BT474 cells 100 nM 4 h Test the inhibitory effect of AZ5104 on HER2T798M signaling PMC5457707
MCF10A cells 100 nM 4 h Test the inhibitory effect of AZ5104 on HER2L869R/T798I signaling PMC5457707
H1975 2 nmol/L 72 hours Evaluate the inhibitory activity of AZ-5104 against T790M mutant cells PMC7745057
Th17 cells above 0.5 μM 5 days AZ5104 inhibits RORγT expression and Th17-related cytokine production in Th17 cells PMC6887705
HepG2 cells 1-5 μM 24 hours AZ5104 acts as an RORγ agonist in HepG2 cells, inducing RORγ-dependent transcription and G6PC gene expression PMC6887705

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CB17 SCID mice H2073-SVD and H2073-ASV xenograft model Oral 50 mg/kg Once daily for 14 days AZ5104 demonstrated significant tumor growth inhibition in H2073-SVD and H2073-ASV xenograft models PMC5932243
Sprague-Dawley rats Rat plasma model Plasma incubation 27 ng/ml 6 hours Investigated the instability of AZ-5104 in rat plasma, finding its relative quantity dropped to 2.96% after 6 hours PMC9354582

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.06mL

0.41mL

0.21mL

10.30mL

2.06mL

1.03mL

20.59mL

4.12mL

2.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Yates JW, Ashton S, et al. Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104. Mol Cancer Ther. 2016 Oct;15(10):2378-2387.

[2]Cross DA, Ashton SE, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.

[3]Floc'h N, Martin MJ, et al. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther. 2018 May;17(5):885-896.

[4]Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem. 2014 Oct 23;57(20):8249-67.

[5]Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE Jr, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL. An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discov. 2017 Jun;7(6):575-585. doi: 10.1158/2159-8290.CD-16-1431. Epub 2017 Mar 8. Erratum in: Cancer Discov. 2019 Feb;9(2):303.

[6]Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.

 

Historical Records

Categories